Стратегия антигипертензивной терапии приатеросклеротическом поражении сонных артерий: рольингибиторов ангиотензинпревращающего фермента
Стратегия антигипертензивной терапии приатеросклеротическом поражении сонных артерий: рольингибиторов ангиотензинпревращающего фермента
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Российское медицинское общество по артериальной гипертензии – Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (3-ий пересмотр.). М., 2008.
2. Hodis HN, Mack WJ, LaBree L et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262–9.
3. Hedblad B, Wikstrand J, Janzon L et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the _-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721–6.
4. Zanchetti A, Agabiti-Rosei E, Dal Paulu C et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media theickness. J Hypertens 1998; 16: 1667–76.
5. Borhani NO, Mercuri M, Borhani PA et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276: 785–91.
6. Zanchetti A, Bold G, Hennig M et al. Calcium antagonist lacidipin slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422–7.
7. Bots ML, Hoes AW, Koudstaal PJ et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96: 1432–7.
8. Burke G, Evans G, Riley W et al. Arterial wall thickness is associated with prvalent cardiovascular diseases in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995; 26: 386–91.
9. Li R, Duncan BB, Metcalf PA et al. B-mode-detected carotid artery plaque in a general population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke 1994; 25: 2377–83.
10. Duncan BB, Metcalf P, Crouse JR et al. Risk factors differ for carotid artery plaque with and without acoustic shadowing. Atherosclerosis Risk in Communities Study Investigators. J Neuroimaging 1997; 7: 28–34.
11. Stevens J, Tyroler HA, Cai J et al. Body weight change and carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1998; 147: 563–73.
12. Chambless LE, Folsom AR, Clegg LX et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000; 151: 478–87.
13. O'Leary DH, Polak JF, Kronmal RA et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14–22.
14. Ogata T, Yasaka M, Yamagishi M et al. Atherosclerosis found on carotid ultrasonography is associated with atherosclerosis on coronary intravascular ultrasonography. J Ultrasound Med 2005; 24: 469–74.
15. Fukuhara M, Geary RL, Diz DI et al. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 2000; 35 (1 Pt. 2): 353–9.
16. Sluimer JC, Gasc JM, Hamming I et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J Pathol 2008; 215 (3): 273–9.
17. Ohishi M, Ueda M, Rakugi H et al. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens 1997; 15 (11): 1295–302.
18. Yagi S, Morita T, Katayama S. Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens Res 2004; 27: 129–35.
19. Feng TC, Ying WY, Hua RJ et al. Effect of valsartan and captopril in rabbit carotid injury. Possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade. J Renin Angiotensin Aldosterone Syst 2001; 2: 19–24.
20. Migdalis IN, Gerolimou B, Kozanidou G et al. Effect of fosinopril sodium on early carotid atherosclerosis in diabetic patients with hypertension. J Med 1997; 28 (5–6): 371–80.
21. Zanchetti A, Crepaldi G, Bond MG et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS – a randomized double-blind trial. Stroke 2004; 35: 2807–12.
22. Lonn EM, Yusuf S, Dzavik V et al. Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and Vitamin E (SECURE). Circulation 2001; 103: 919–25.
23. MacMahon S, Sharpe N, Gamble G et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 2000; 36: 438–43.
24. Hosomi N, Mizushige K, Ohyama H et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 2001; 32: 1539–45.
25. Furberg CS, Adams HP, Applegate WB et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90: 1679–87.
26. Crouse JR III, Byington RP, Bond MG et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75: 455–9.
27. Mercuri M, Bond MG, Sirtori CR et al. Pravastatin reduces carotid-intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996; 101: 627–34.
28. MacMahon S, Sharpe N, Gamble G et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis. Results of the LIPID Atherosclerosis Substudy. Circulation 1998; 97: 1784–90.
2. Hodis HN, Mack WJ, LaBree L et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262–9.
3. Hedblad B, Wikstrand J, Janzon L et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the _-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721–6.
4. Zanchetti A, Agabiti-Rosei E, Dal Paulu C et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media theickness. J Hypertens 1998; 16: 1667–76.
5. Borhani NO, Mercuri M, Borhani PA et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276: 785–91.
6. Zanchetti A, Bold G, Hennig M et al. Calcium antagonist lacidipin slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422–7.
7. Bots ML, Hoes AW, Koudstaal PJ et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96: 1432–7.
8. Burke G, Evans G, Riley W et al. Arterial wall thickness is associated with prvalent cardiovascular diseases in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995; 26: 386–91.
9. Li R, Duncan BB, Metcalf PA et al. B-mode-detected carotid artery plaque in a general population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke 1994; 25: 2377–83.
10. Duncan BB, Metcalf P, Crouse JR et al. Risk factors differ for carotid artery plaque with and without acoustic shadowing. Atherosclerosis Risk in Communities Study Investigators. J Neuroimaging 1997; 7: 28–34.
11. Stevens J, Tyroler HA, Cai J et al. Body weight change and carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1998; 147: 563–73.
12. Chambless LE, Folsom AR, Clegg LX et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000; 151: 478–87.
13. O'Leary DH, Polak JF, Kronmal RA et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14–22.
14. Ogata T, Yasaka M, Yamagishi M et al. Atherosclerosis found on carotid ultrasonography is associated with atherosclerosis on coronary intravascular ultrasonography. J Ultrasound Med 2005; 24: 469–74.
15. Fukuhara M, Geary RL, Diz DI et al. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 2000; 35 (1 Pt. 2): 353–9.
16. Sluimer JC, Gasc JM, Hamming I et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J Pathol 2008; 215 (3): 273–9.
17. Ohishi M, Ueda M, Rakugi H et al. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens 1997; 15 (11): 1295–302.
18. Yagi S, Morita T, Katayama S. Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens Res 2004; 27: 129–35.
19. Feng TC, Ying WY, Hua RJ et al. Effect of valsartan and captopril in rabbit carotid injury. Possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade. J Renin Angiotensin Aldosterone Syst 2001; 2: 19–24.
20. Migdalis IN, Gerolimou B, Kozanidou G et al. Effect of fosinopril sodium on early carotid atherosclerosis in diabetic patients with hypertension. J Med 1997; 28 (5–6): 371–80.
21. Zanchetti A, Crepaldi G, Bond MG et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS – a randomized double-blind trial. Stroke 2004; 35: 2807–12.
22. Lonn EM, Yusuf S, Dzavik V et al. Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and Vitamin E (SECURE). Circulation 2001; 103: 919–25.
23. MacMahon S, Sharpe N, Gamble G et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 2000; 36: 438–43.
24. Hosomi N, Mizushige K, Ohyama H et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 2001; 32: 1539–45.
25. Furberg CS, Adams HP, Applegate WB et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90: 1679–87.
26. Crouse JR III, Byington RP, Bond MG et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75: 455–9.
27. Mercuri M, Bond MG, Sirtori CR et al. Pravastatin reduces carotid-intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996; 101: 627–34.
28. MacMahon S, Sharpe N, Gamble G et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis. Results of the LIPID Atherosclerosis Substudy. Circulation 1998; 97: 1784–90.
Авторы
В.В.Фомин
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.